Loading people...
Dr. Frank Kalkbrenner is the Managing Director and Global Head of the Boehringer Ingelheim Venture Fund, based in Ingelheim am Rhein, Germany. He oversees a corporate venture portfolio with over €300 million under management, directing investments across early-stage biotechnology and digital health startups. Kalkbrenner serves on the boards of eTheRNA and Brainomix, and previously held board positions at Hookipa Biotech and STAT Diagnostica before its acquisition by Qiagen. Before transitioning to venture capital in 2010, he spent over a decade in pharmaceutical research at Boehringer Ingelheim, including serving as Vice President of R&D Licensing. He earned his medical degree and a PhD in Pharmacology from Freie Universität Berlin, completing academic research at the Max Planck Institute for Molecular Genetics. His current professional focus centers on leveraging his pharmacological expertise to identify and scale novel therapeutic technologies.
Frank Kalkbrenner is a distinguished Managing Director at the Boehringer Ingelheim Venture Fund, a corporate venture capital arm dedicated to investing in pioneering life science companies. With a profound background in drug discovery and development, Dr. Kalkbrenner plays a crucial role in identifying and nurturing innovative startups that align with Boehringer Ingelheim's strategic therapeutic areas. His leadership helps to drive the fund's mission of fostering scientific breakthroughs and translating them into tangible patient benefits.
At the Boehringer Ingelheim Venture Fund, Frank Kalkbrenner's investment focus is primarily on early-stage therapeutic companies. He seeks out ventures with disruptive scientific platforms and promising drug candidates across a range of disease areas. Key investment sectors include immunology, inflammation, oncology, respiratory diseases, and central nervous system disorders. Dr. Kalkbrenner is particularly interested in companies that demonstrate strong scientific rigor, novel mechanisms of action, and the potential to address significant unmet medical needs. He works closely with portfolio companies, offering strategic guidance and leveraging Boehringer Ingelheim's extensive R&D network to accelerate their development.
Dr. Kalkbrenner's extensive career background provides a solid foundation for his role in venture capital. Before joining the Boehringer Ingelheim Venture Fund, he held various senior leadership positions within Boehringer Ingelheim's research and development organization. His prior roles included leading significant therapeutic areas and contributing to the advancement of numerous drug candidates from early discovery through preclinical and clinical stages. This hands-on experience in pharmaceutical R&D, coupled with his Ph.D. in Molecular Biology, equips him with a unique perspective on evaluating scientific innovation and commercial viability in the life sciences sector. His deep understanding of the drug development lifecycle is invaluable in assessing potential investments and guiding portfolio companies through complex scientific and regulatory landscapes.
While specific individual "notable investments" are often attributed to the fund as a whole, Frank Kalkbrenner has been instrumental in shaping the Boehringer Ingelheim Venture Fund's robust portfolio. His contributions have supported numerous companies that are developing next-generation therapies, contributing to the fund's reputation as a key player in early-stage life science investing. His strategic insights and scientific acumen are vital in identifying the most promising opportunities that have the potential to deliver significant impact in healthcare. Through his work, Dr. Kalkbrenner continues to champion scientific innovation and facilitate the growth of companies poised to revolutionize medicine.
Frank Kalkbrenner is a Managing Director at the Boehringer Ingelheim Venture Fund, a corporate venture capital fund that invests in early-stage life science companies.
Frank Kalkbrenner invests in early-stage therapeutic companies, focusing on areas such as immunology, oncology, respiratory diseases, and central nervous system disorders, seeking disruptive scientific platforms.
Frank Kalkbrenner works at the Boehringer Ingelheim Venture Fund, which is the corporate venture capital arm of Boehringer Ingelheim, based in Germany and with a global investment reach.
